How Robots Are Introducing A New Dimension To Healthcare Service Delivery

Pharmaceutical

What Is Herbal Medicine? A Comprehensive Explor...

Herbal medicine, also known as traditional medicine, botanical medicine, herbalism, or natural medicine, is an ancient healing practice that dates back thousands of years. Herbal Medicine is part o...

Aug 02, 2023

Pharma News for GSK, Biogen, Citius
FDA Expands GSK’s Jemperli Approval; Biogen to Acquire Reata Pharma; Enhertu Shows Survival Boost in HER2+ Solid Tumors; FDA Rejects Citius’ Revived IL-2 Therapy; FDA Fast Track designation to IVS-3001 for RCC; EU Orphan Drug Designation to Biohaven’s Taldefgrobep Alfa

FDA Expands GSK’s Jemperli Approval for Endometrial Cancer GSK plc announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with mismatch repair deficient...

Find More
cocaine-use-disorder-cud-treatment
New Horizons in Cocaine Use Disorder (CUD) Treatment Space

Cocaine use disorder also known as cocaine dependence is a chronic condition that affects millions of people worldwide. Cocaine is a highly addictive central nervous system stimulant derived from the leaves of the coca plant and produces a range of effects on the mind and body, including short-lived euphoria, incre...

Find More
insomnia-treatment
Fewer Sleepless Nights Over, Drugs for Insomnia Treatment

“Sleep is a fundamental pillar of our overall health and well-being, and a continued lack of sleep can significantly impact many aspects of daily life”. Insomnia and its symptoms Insomnia is a common sleep-wake disorder where one has difficulty initiating or maintaining sleep or dissatisfaction with sleep q...

Find More

More Views & Analysis

Pharma News for Gilead, Ambrx, Mirati
Gilead’s Magrolimab Plus Azacitidine for MDS; FDA Approveds VANFLYTA for Newly Diagnosed AML; FDA Awards Fast Track Designation to ARX517 mCRPC; EMA Rejects Mirati’s Krazati; Harmony Phase III Pitolisant Trial for PWS Patients; Belite Bio’s Phase 3 DRAGON Trial of Tinlarebant for STGD

Gilead To Discontinue Phase III ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS Gilead Sciences, Inc. reported that the Phase III ENHANCE study in higher-risk myelodysplastic syndromes (MDS) has been halted due to futility based on a planned analysis. The safety data in this trial are consistent ...

Find More

multiple-sclerosis-treatment
Revolutionizing Multiple Sclerosis Treatment: A New Era of Therapies

Multiple sclerosis is an unpredictable, autoimmune disease that affects the central nervous system. Multiple sclerosis is believed to impact almost 1 million Americans, and the disease manifests itself in a variety of ways. Because nerves are affected in different ways and exhibit a variety of symptoms, no two case...

Find More

beyfortus-for-respiratory-syncytial-virus-treatment
Beyfortus: A New Respiratory Syncytial Virus (RSV) Drug for Toddlers

Sanofi’s immunization strategy is taking shape, owing to an authorization that could drive the company and its partner AstraZeneca to the forefront of the respiratory syncytial virus (RSV) treatment battle. The FDA approved Sanofi and AstraZeneca’s monoclonal antibody Beyfortus, also known as nirsevimab, as a preve...

Find More

Pharma News for Eli Lilly, Alnylam, Elevar
Lilly to Acquire Versanis; FDA Approves Beyfortus for RSV in Infants; Alnylam Presented Updates on Interim Phase 1 Results for ALN-APP; FDA Accepts NDA for Rivoceranib Plus Camrelizumab; FDA Fast Track Designation to Karyopharm’s Selinexor; Adcentrx’s IND Application for ADRX-0706

Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases Eli Lilly & Company and Versanis Bio announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical firm focused on the discovery of novel medications for the treatment of cardiometab...

Find More

Inflammatory Myositis Treatment Outlook
Analyzing Strategies in Polymyositis and Dermatomyositis Treatment 

Inflammatory myositis refers to a group of disorders affecting the muscles and may be associated with different causes such as infection, drug toxicity, trauma, and autoimmune diseases. The most prominent cause of myositis is an autoimmune disease, typically known as idiopathic inflammatory myopathy (IIM). The indi...

Find More

biomarins-roctavian-first-hemophilia-a-gene-therapy
The Future is Here: BioMarin’s Roctavian First Hemophilia A Gene Therapy Paving the Way for a Cure

Hemophilia A is a rare genetic bleeding disorder that primarily affects males. Hemophilia A is the most common type of hemophilia, accounting for approximately 80% of all cases. It is estimated to occur in about 1 in 5,000 to 10,000 male births. As per the Centers for Disease Control (CDC) (2020), the estimated pre...

Find More

Cancer, an immunologic condition that can begin in any organ or tissue of the body is the second lea.....

Find More

Today, Artificial Intelligence has been used effectively in data processing, drug discovery, aiding .....

Find More

Doctors and scientists have recognized that traditional, complementary and alternative therapies hav.....

Find More

According to WHO, Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death g.....

Find More

The coronavirus outbreak has affected thousands of people in at least 186 countries which has also a.....

Find More

Schizophrenia is a severe mental illness that interferes with a person's ability to think clearly, m.....

Find More